Partner David Rosen was quoted in a Newsweek article published on May 1, 2014, titled “Be Still, My Bioficial Heart.” The article explained the benefits and challenges of creating a “bioficial heart,” which researchers at the University of Louisville recently announced could be developed using living cells from a potential transplant patient combined with artificial materials to create a fully functional 3-D printed heart. Given that the U.S. Food and Drug Administration (FDA) is many years out from approving lab-built organs for patients, Rosen said, “The potential challenges include demonstrating that the organs will function as predicted, demonstrating the sustainability of these organs once transplanted and obtaining approval to test and market these from [the] FDA.”
People
Related News
14 February 2025
In the News
Judith Waltz on Trump Administration Deregulation Order, Impact on CMS
Foley & Lardner LLP partner Judith Waltz commented on the Trump administration's executive order requiring federal agencies cut ten regulations for each newly created one in the Modern Healthcare article, "CMS may evade Trump's sweeping deregulation order."
14 February 2025
In the News
Christopher Swift Comments on FCPA Enforcement Pause
Foley & Lardner LLP partner Christopher Swift commented on the Trump administration's executive order pausing enforcement of the Foreign Corrupt Practices Act in The New York Times article, "Moves by Trump and Bondi Raise Hopes of Those Accused of Foreign Corruption."
13 February 2025
In the News
Nikhil Pradhan on FDA Draft AI Drug Guidance – 'The industry is very much evolving'
Foley & Lardner LLP senior counsel Nikhil Pradhan shared insight on recent draft guidance from the U.S. Food and Drug Administration's in the MedCentral article, "FDA Draft Guidance Addresses Drug Submissions that Use AI Data."